BIOMAT Database Logo BIOMAT Database Logo

The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls. 1989

K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Department of Psychiatry, University of Würzburg, Federal Republic of Germany.

Twenty subjects (10 patients with a major depressive episode and 10 individually matched healthy controls) received 100 micrograms synthetic human corticotropin-releasing hormone (hCRH) as an i.v. bolus dose. Healthy subjects and depressed patients exhibited a significant increase of plasma somatostatin (SRIH) concentrations with no difference between both comparison groups. Compared to controls, depressed patients showed a significant attenuation of corticotropin (ACTH) responses, while cortisol secretion in response to hCRH was normal. No correlations were found among basal plasma concentrations of SRIH, ACTH or cortisol and SRIH, ACTH or cortisol responses following hCRH. These findings are compatible with the hypothesis that hypothalamic-pituitary-adrenal (HPA) hyperactivity in the depressive state may primarily be due to central hypersecretion of CRH and support the view of a hCRH-induced SRIH secretion which is not related to HPA dysfunction associated with major depression.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment.
January 1998, Depression and anxiety,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Corticotropin-releasing factor in plasma of depressed patients and controls.
January 1986, Lancet (London, England),
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Influence of human corticotropin-releasing hormone and adrenocorticotropin upon spontaneous growth hormone secretion.
November 1991, Neuroendocrinology,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Putative somatostatin suppression potentiates adrenocorticotropin secretion driven by ghrelin and human corticotropin-releasing hormone.
September 2007, The Journal of clinical endocrinology and metabolism,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
July 1992, Psychiatry research,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls.
October 1992, Neuroendocrinology,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients.
January 1988, Journal of affective disorders,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
CSF corticotropin-releasing hormone in depressed patients and normal control subjects.
May 1987, The American journal of psychiatry,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Ghrelin potentiates growth hormone secretion driven by putative somatostatin withdrawal and resists inhibition by human corticotropin-releasing hormone.
June 2006, The Journal of clinical endocrinology and metabolism,
K P Lesch, and E Widerlöv, and R Ekman, and G Laux, and R Rupprecht, and H M Schulte, and H Beckmann
Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients.
May 1990, Breast cancer research and treatment,
Copied contents to your clipboard!